23/05/18. Mood changes in postmenopausal women treated with progesterone
|
|
- Garey Gibbs
- 5 years ago
- Views:
Transcription
1 //8 Is Premenstrual syndrome (PMS) / Premenstrual dysphoric disorder (PMDD) due to paradoxical effects of progesterone metabolites and possible to treat? Torbjörn Bäckström MD., PhD., Professor Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, Umeå, Sweden. Support: EU structural fund, Swedish research council Medicine, Västerbottens county, Umeå Municipal, Northen Sweden health region Disclosure: Owns shares in: Umecrine AB, Asarina Pharma AB, Umecrine Cognition AB Symptom and hormone variations in patients with PMDD/PMS n=8 cycles in 9 patients Bäckström et al 98 Mood changes in postmenopausal women treated with progesterone Cyclicity disappears in anovulatory cycles Progesterone but not placebo is give negative mood symptoms in postmenopausal women receiving estrogen / progesterone or placebo N=8, two cycles in the same persons with one spontaneous anovulatory cycle Hammarbäck et al, Acta Endocrinol 99; : - Negative mood score 8 Estradiol, mg/day Progesterone mg/day or placebo Day of cycle Andreén et al, Psyconeuroendocrinol Synthesis of GABA-A receptor modulating steroids Mitochondrial transport of cholesterol is rate limiting for allopregnanolone synthesis in brain. Scientific background The GABAA receptor TSPO GAMS -OH Progesterone -deoxycortisol Cortisol osterone Anatomical distribution of GABAA receptor subclasses. α is very sensitive to allopregnanolone aa-cortisol α-dht Androstanediol Bäckström et al, Springer NY 8 Wisden et al. J. Neurosci. ;99: The GABA system CNS s general moderating system The GABAA receptor is a chloride channel The GABA-A receptor is target for - GABA - GABA-A receptor modulating steroids (GAMS) - barbiturates - benzodiazepines - ethanol emotional center Sensitive to GAMS memory center α amygdala Thalamus, globus pallidus
2 Allopregnanolone, nmol/l Irritabillity, score Depression, score //8 Symptom and allopregnanolone relation during menstrual cycle in women with PMDD Negative mood curve correlates with allopregnanolone serum concentration r=.;p<.. n=8 cycles in 9 patients Wang et al. J. Clin. Endocrinol. Metab. 99;8:-8 Bäckström et al. CNS Drugs. ;():-. Ovulation Menstration 8 Days in idealizised menstrual cycle GABA steroid Paradox Why is that? In the menstrual cycle an increase in allopregnanolone is related to development of negative mood but In animal studies allopregnanolone is anxiolytic, antiepileptic, and sedative Benzodiazepins, barbiturates, alcohol and allopregnanolone have a bimodal action. High concentrations are anxiolytic, anti-aggressive, sedative/anaesthetic, and antiepileptic. Wang MD, et al. Int Rev Neurobiol ;:-9. Paul SM, Purdy RH. Neuroactive steriods. FASEB J 99;:-. Bäckström T, et al. Steroids in relation to epilepsy and anaesthesia. Ciba Found Symp 99;:-. Low concentrations induce strong negative mood, irritability and aggression in % of individuals. Moderate changes in % of individuals. Beauchamp MH, et al. Allopregnanolone, place aversion in rats. Pharmacol Biochem Behav ;:9-. Fish EW, et al. Alcohol, allopregnanolone and aggression in mice. Psychopharmacology ;:-8. Lee GP, et al. Severe behavioral complications following amobarbital injection. Neurology 988;8:-. Kurthen M, et al. Severe negative emotional reactions in amytal procedures. Cortex 99;:-. Masia SL, et al. Emotional outbursts during intracarotid amobarbital procedure. Neurology ;:9-9. Yoshimura H, et al. Psychotropic drugs and maternal aggression in mice.psychopharm.989;9:9 Miczek K, et al. Alcohol, benzodiazepine GABAa receptor and aggression. Rec. Dev Alcohol 99;:9- Wenzel et al. Negative reaction on midazolam. J Am Soc Echocardiogr ; : 9-. GABA receptor sensitivity is different in PMDD - the paradoxical response Dysphoria Anxiety Irritability Baseline Anxiolysis Sedation Drug response Expected effect Example: -% of patients given a low dose benzodiazepine respond with severe anxiety and aggression and -% with a moderate paradoxical response rather than an expected sedation. This is overcome by administration of a higher dose. Among women -8% have PMDD, -% severe PMS. Paradoxical effect Physiological concentration range Drug concentration / Dose Fig from Löfgren 9 Effects of allopregnanolone and alcohol on the frequency of attack bites in mice with alcohol-heightened aggressive behavior Negative mood relates to increasing plasma allopregnanolone in postmenopausal women taking oral progesterone Progesterone / allopregnanolone (Low concentration) increases amygdala reactivity in women on aversive pictures fmri. Indicates paradoxical effect. Mice Miczek Human ** Andréen et al Negative mood * * * Allopregnanolone and alphaxalone has similar biphasic effect as alcohol on aggressive behavior in mice Physiological range during luteal phase > Allopregnanolone (nmol/l) Allopregnanolone in physiological range has a biphasic relation to negative mood symptoms in humans Progesterone / Allopregnanolone Effect of oral progesterone administration on responses in amygdala assessed with fmri van Wingen GA, van Broekhoven, Verkes RJ, Petersson KM, Bäckström T, Buitelaar JK, Fernandez G. Progesterone selectively increases amygdala reactivity in women. Molecular Psychiatry. 8 ;:- Plasma concentrations after oral Progesterone
3 //8 High progesterone / allopregnanolone reduce activity in amygdala at aversive pictures. The expected effect and opposite to low concentration Inhibition of allopregnanolone effect van Wingen G, van Broekhoven F, Verkes RJ, Petersson KM, Bäckström T, Buitelaar J, Fernandes G. How progesterone impairs memory for biologically salient stimuli in healthy young women. J Neurosci ;:- with Reduced fmri is obtained with Benzodiazepines in a dose that cause anxiolytic effects. Paulus, et al. Arch. Gen. Psychiatry., Plasma concentrations after oral progesterone Right amygdala at high Progesterone Phase IIa clinical study Exploratory Phase IIa clinical study (UM) completed Ø Double-blind, randomised, placebo-controlled study. Ø Population: of women Ø Criteria: PMDD verified according to DSM-IV by prospective ratings during at least two menstrual cycles using the validated DRSP scale Ø showing ovulation during cycle Ø having usable ratings and Ø given doses of Ø Sub group population: The patients that were given as intended during the symptomatic premenstrual period. Ø Primary endpoint: change in symptoms and impact of symptoms assessed by daily ratings using the validated DRSP tool for PMDD* Ø Grading of psychological parameters and physical symptoms Ø Severity of everyday social functioning and work performance graded Ø graded rating scale ranging from not at all to extreme Overwhelming response from patients wanting to enrol in the trial Outcome conclusions Sepranolone is safe and well tolerated, alleviates symptoms and improves symptom-induced impairment in daily life GABA-A receptor modulating steroids (GAMS), metabolites of stress and sex- hormones, induce symptoms and disorders. Treatment by blocking GAMS Using an unique new principle * EMA and FDA guidelines GABA-A modulating steroid antagonist (GAMSA) Patients treated with Sepranolone. Total population (n=) including patients not treated during the symptomatic premenstrual period. All treated patients, (intention to treat analysis) including patients not treated according to the study protocol during the symptomatic period. Total premenstrual symptom score (p=.) n= n= Sub-group treated as intended (n=). Sub-group of patients that started according to the study protocol showed highly significant beneficial effects of Sepranolone on: Total premenstrual symptom score (p=.) a)bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC)-A randomized controlled trial. Psychoneuroendocrinology. Jun;8:- n= n= Sepranolone Sepranolone twice as effective as YAZ Sepranolone has an effect size of.a in total symptom reduction compared to placebo, vs. YAZ standardized effect size of.b b)yonkers, et.al.efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Ob&Gyn..();9. Summarized impairment scores during the pre and menstrual cycles in the placebo and UC treated groups Thank You
4 //8 PMS and oral contraceptives Bäckström et al 99 Treatment of women with PMDD using GnRH-agonist for induction of anovulation in a doubleblind cross-over study, n= Pre Buserelin Hammarbäck,Bäckström 988 Breast tenderness Irritability score Cherful score Pre GnRH agonist - - Sepranolone modulates the allopregnanolone-induced decrease in Saccadic Eye Velocity (SEV) in healthy women. - clinical trial protocol UNC Sepranolone modulates the allopregnanolone-induced decrease in SEV in healthy women - data from clinical trial report Exploratory single-center, pharmacodynamic study in healthy women during follicular phase Single-blind, cross-over design Intravenous bolus administration of ALLO alone or ALLO + Sepranolone (two doses). mg/kg allopregnanolone +. mg/kg Sepranolone IV +. mg/kg Sepranolone IV Assessment of GABA A receptor activity (SEV and sedation) before and following drugs Bengtsson SKS, Nyberg S, Hedström H, Zingmark E, Jonsson B, Bäckström T, Bixo M. Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology. Feb;:- AUC -8 change in saccadic velocity (min Deg/sec) following single i.v. injections of allo alone or allo in combination with Sepranolone Allo Allo + low dose Sepranolone Allo + high dose Sepranolone P=. P=. Result of primary analysis: SEV AUC allo vs. allo+sepranolone (both Sepranolone doses combined) p=. Bengtsson SKS, Nyberg S, Hedström H, Zingmark E, Jonsson B, Bäckström T, Bixo M. Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology. Feb;:-) Patients treated as intended in protocol Sub group analysis Analysis of the sub-group of patients that started according to the study protocol showed highly significant beneficial effects of UC on: Sepranolone meets FDA s primary endpoint* in phase IIa study. Double-blind, placebo controlled trial in of patients Patients received five doses over days from ovulation Two doses, mg and mg tested; pooled data below *Total symptom score of symptoms Total premenstrual symptom score (p=.) Cardinal negative mood score (p=.) Impairment score (p=.), which measures the impact of symptoms on daily life in the week prior to menstruation Overall effect showed an 8 % correction of premenstrual symptoms Statistically significant reduction in total premenstrual symptom score (p=.) compared to placebo Sepranolone twice as effective as YAZ by indirect comparison Sepranolone has a standardized effect size of. in total symptom reduction as compared to placebo, vs. YAZ standardized effect size of. (*KA Yonkers, et.al.efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Ob&Gyn..();9). n= n= N= n= Sepranolone Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC)-A randomized controlled trial. Psychoneuroendocrinology. Jun;8:-
5 //8 Highly significant effect in Treated as Intended population Highly statistically significant reduction in pre-menstrual symptom score in treated as intended population (p =.) Some patients initiated too early and may thus have been drug-free during the days with peak ALLO concentration just prior to next menstruation Self rated Irritability Scores in women with PMDD in different situations placebo citalopram: continuous citalopram: semiintermittent citalopram: intermittent n= n= Sepranolone Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC)-A randomized controlled trial. Psychoneuroendocrinology. Jun;8:- Wikander et al 998 Mean (SE) symptom changes in women with PMDD and Controls using daily prospective symptom ratings with the Cyclicity Diagnoser Depression Irritability PMDD Epidemiology of Premenstrual Symptoms and Complaints All women with menstrual cycles As many as -8% have premenstrual symptoms -% PMS -8% PMDD Sundström-Promaa et al 999 Anxiety Days of menstrual cycle ). de la Gandara Martin and de Diego Herrero, 99; Hylan et al., 999; Ramcharan et al., 99; Wittchen et al., ; Woods et al., 98 ). Angst et al., ; Wittchen et al., ). American Psychiatric Association, 99; Andersch et al., 98; Angst et al., ; Campbell et al., 99; Chawla et al., ; Cohen et al., ; Deuster et al., 999; Gehlert and Hartlage, 99; Johnson et al., 988; Ramcharan et al., 99; Rivera-Tovar and Frank, 99; Sveindottir and Backstrom, ; Wittchen et al., ; Woods et al., 98 Diagnosis Criteria Symptoms Required Duration of symptoms PMS VS PMDD PMS PMS PMDD ICD- ACOG DSM-IV of mood of mood - days days Synptom free - - days postmens Functional Impairment Prospective Charting days postmens Not required Required Required Not required cycles Required ( cycles) PMDD in DSM-IV A. Five symptoms, one from symptoms below, in most menstrual cycles the past year, present the premenstrual week absent post menstrual week Depression, Irritability, Anxiety/tension, Affect lability Decreased interest, Difficulty in concentrating, Fatigue, Out of control, Insomnia Change in appetite, Breast tenderness, Swelling B. Markedly Interfere with work, social-and family-life C. Should not be an exacerbation D. Criteria A-C must be confirmed by daily prospective symptom ratings in two consecutive menstrual cycles
6 //8 PMS ACOG A. Two symptoms, one from symptoms below, in most menstrual cycles the past year, present days during the premenstrual week absent post menstrual week Depression, Irritability, Anger burst Anxiety/tension, Confusion, Social withdrawal Change in appetite, Breast tenderness, Abdominal bloating B. Interfere with work, social-and family-life C. Should not be an exacerbation D. Criteria A-C must be confirmed by daily prospective symptom ratings in two consecutive menstrual cycles PMS: ICD - - CM CRITERIA Only ONE of the following symptoms required: Psychological discomfort Feeling of bloating / weight gain Breast tenderness Swelling of hands and feet Various aches and pains Poor concentration Sleep disturbance Change in appetite Pure PMS PM aggravation Hammarbäck et al 989 Hammarbäck et al 989 No PMS Comparison between severe PMS / PMDD patients and controls with regard to symptoms during menstrual cycle Cyclicity Diagnoser (CD) scale daily rating = absence of symptoms, Hammarbäck et al = maximal severity of symptoms M. Bixo et al. / Psychoneuroendocrinology (Sundström et al., 999). ()
Chapter 20 Neuroactive Steroids in Brain and Relevance to Mood
Chapter 20 Neuroactive Steroids in Brain and Relevance to Mood Torbjörn Bäckström 1, Lotta Andréen 1, Marie Bixo 1, Inger Björn 1, Guillén Fernández 2, Inga-Maj Johansson 1, Per Lundgren 1, Magnus Löfgren
More informationHormonal contraception and PMS. Inger Sundström Poromaa Department of Women s and Children s Health Uppsala University
Hormonal contraception and PMS Inger Sundström Poromaa Department of Women s and Children s Health Uppsala University Definitions Premenstrual syndrome (PMS) ICD 10: Two symptoms, at least one psychological,
More informationProgesterone effects during sequential hormone replacement therapy
European Journal of Endocrinology (2003) 148 571 577 ISSN 0804-4643 CLINICAL STUDY Progesterone effects during sequential hormone replacement therapy Lotta Andréen, Mari Bixo, Sigrid Nyberg, Inger Sundström-Poromaa
More informationPrevalence of Premenstrual Syndrome in Autism: a Prospective Observer-rated Study
The Journal of International Medical Research 2008; 36: 268 272 Prevalence of Premenstrual Syndrome in Autism: a Prospective Observer-rated Study H OBAYDI 1 AND BK PURI 2 1 Hertfordshire Partnership Foundation
More informationAllopregnanolone and Mood
UMEÅ UNIVERSITY MEDICAL DISSERTATIONS New Series No 1022 ISSN 0346-6612 ISBN 91-7264-065-0 From the Department of Clinical Science, Obstetrics and Gynecology, Umeå University, Umeå, Sweden Allopregnanolone
More informationCitation for the original published paper (version of record): N.B. When citing this work, cite the original published paper.
http://www.diva-portal.org This is the published version of a paper published in Journal of neuroendocrinology (Print). Citation for the original published paper (version of record): Bixo, M., Johansson,
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWomen with PTSD have a changed sensitivity to GABA-A receptor active substances
Psychopharmacology (2016) 233:2025 2033 DOI 10.1007/s00213-014-3776-y ORIGINAL INVESTIGATION Women with PTSD have a changed sensitivity to GABA-A receptor active substances Anna Tiihonen Möller & Torbjörn
More informationThe biology of menstrually related. Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives REPORTS. Patricia J.
REPORTS Ovulation Suppression of Premenstrual Symptoms Using Oral Contraceptives Patricia J. Sulak, MD Abstract Managing premenstrual symptoms at the most fundamental level necessitates careful consideration
More informationWomen s Mental Health
Women s Mental Health Linda S. Mullen, MD Director, Women s Mental Health Assistant Professor of Clinical Psychiatry in OB/GYN Columbia University & NewYork Presbyterian Hospital Departments of Psychiatry
More informationPremenstrual dysphoric disorder (PMDD)
EXPANDING CHOICES IN TREATING PREMENSTRUAL DYSPHORIC DISORDER * Bruce Kessel, MD* ABSTRACT Over the past 2 decades, considerable progress has occurred in the understanding, diagnosis, and clinical management
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreating Mood Disorders Associated with PMS and Perimenopause
Treating Mood Disorders Associated with PMS and Perimenopause Anna M. Cabeca, DO, FACOG, ABAARM HRT Symposium Savannah GA July 14-16, 2016 2016. All Rights Reserved. 1 Disclosure Anna M. Cabeca, DO, FACOG,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe burden of mental disorders, such as depression and anxiety, fall disproportionately on women of childbearing and childrearing age.
The burden of mental disorders, such as depression and anxiety, fall disproportionately on women of childbearing and childrearing age. Psychiatric Clinics of North America, 2007 Rates of severe mental
More informationFluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder
human psychopharmacology Hum Psychopharmacol Clin Exp 2003; 18: 191 195. Published online 23 December 2002 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hup.470 Fluoxetine versus Vitex
More informationPremenstrual Syndrome among College of Nursing Students
Premenstrual Syndrome among College of Nursing Students Aveen Fattah Haji * Dr. Badia Muhamad Najib ** ABSTRACT Background and Objectives: Premenstrual syndrome which affects women during their reproductive
More informationReproductive hormones and epilepsy
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Reproductive hormones and epilepsy Gerhard
More informationWomen s Issues in Epilepsy. Esther Bui, Epilepsy Fellow MD, FRCPC
Women s Issues in Epilepsy Esther Bui, Epilepsy Fellow MD, FRCPC How are women different? Different habitus Different metabolism Different co-morbidities Different psychosocial stigma Different hormonal
More informationUmeå University (Sweden) Professor of obstetrics and gynecology and senior consultant
Curriculum vitae PERSONAL INFORMATION Marie Bixo WORK EXPERIENCE March 2014 Present Professor Professor of obstetrics and gynecology and senior consultant February 2012 March 2014 Professor Karolinska
More informationTreatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol
REVIEW Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol Domenico De Berardis 1,2,3 Nicola Serroni 2 Rosa Maria Salerno 1 Filippo Maria
More informationPARADOXICAL EFFECTS OF GABA-A MODULATORS MAY EXPLAIN SEX STEROID INDUCED NEGATIVE MOOD SYMPTOMS IN SOME PERSONS
Neuroscience 191 (2011) 46 54 REVIEW PARADOXICAL EFFECTS OF GABA-A MODULATORS MAY EXPLAIN SEX STEROID INDUCED NEGATIVE MOOD SYMPTOMS IN SOME PERSONS T. BÄCKSTRÖM, a * D. HAAGE, a M. LÖFGREN, a I. M. JOHANSSON,
More informationExploring New Treatment Options. case study on PMDD and the current recommendations for treatment. A Case Study on PMDD
M A N A G I N G PMS& PMDD Exploring New Treatment Options Most women of reproductive age some 85 percent experience recurrent mood and somatic symptoms with their menstrual cycles (ACOG, 2000). The symptoms
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationMicronutrient Intake and Premenstrual Syndrome
University of Massachusetts Amherst ScholarWorks@UMass Amherst Open Access Dissertations 9-2011 Micronutrient Intake and Premenstrual Syndrome Patricia O. Chocano-Bedoya University of Massachusetts Amherst,
More informationPREMENSTRUAL SYNDROME: PREVALENCE IN STUDENTS OF THE UNIVERSITY OF CALABAR, NIGERIA
African Journal of Biomedical Research, Vol. 7 (2004); 45-50 ISSN 1119 5096 Ibadan Biomedical Communications Group Full Length Research Article PREMENSTRUAL SYNDROME: PREVALENCE IN STUDENTS OF THE UNIVERSITY
More informationWomens Early Years. Nayan Patel PharmD
Womens Early Years. Nayan Patel PharmD Dr. Katharina Dalton (OBGYN) Treating PMS since 1953 with Dr. Greene (Endocrinologist) This is the 6 th edition published in 1999 Definition * PMS - is a group of
More informationTolerance to allopregnanolone with focus on the GABA-A receptor
REVIEWbph_1059 311..327 British Journal of Pharmacology DOI:10.1111/j.1476-5381.2010.01059.x www.brjpharmacol.org Tolerance to allopregnanolone with focus on the GABA-A receptor Sahruh Turkmen 1,2, Torbjorn
More informationPremenstrual Syndrome
page 1 Premenstrual Syndrome Q: What is premenstrual syndrome (PMS)? A: Premenstrual syndrome (PMS) is a group of symptoms linked to the menstrual cycle. PMS symptoms occur in the week or two weeks before
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen
American Journal of Obstetrics and Gynecology (2006) 195, 1311 9 www.ajog.org Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen Andrea L. Coffee, PharmD,* Thomas
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More information4/29/2015. Dr. Carman Gill Wednesday, April 29th
Dr. Carman Gill Wednesday, April 29th 1 Impacted diagnoses Major changes and rationale Special considerations Implications for counselors A sustained condition of prolonged emotional dejection, sadness,
More informationPlacebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder
(2007) 32, 153 161 & 2007 Nature Publishing Group All rights reserved 0893-133X/07 $30.00 www.neuropsychopharmacology.org Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual
More informationDo Ovarian Hormones Affect Somatosensation, Pain, and Mood?
Gender Aspects in Cognitive Neuroscience Do Ovarian Hormones Affect Somatosensation, Pain, and Mood? Laboratory of Cognitive Neuroscience and Women s Health Department of Pyschology and School of Public
More informationPostpartum Depression. Deborah Kim, M.D. Assistant Professor Department of Psychiatry
Postpartum Depression Deborah Kim, M.D. Assistant Professor Department of Psychiatry drkim@upenn.edu Objectives Describe the difference between baby blues and postpartum depression (PPD) Describe the prevalence
More informationPremenstrual Syndrome, Premenstrual Dysphoric Disorder, and Beyond: A Clinical Primer for Practitioners
CLINICAL GYNECOLOGIC SERIES: AN EXPERT S VIEW We have invited select authorities to present background information on challenging clinical problems and practical information on diagnosis and treatment
More informationBiruk Kelbessa*, Buzinesh Guteta, Fikiru Negese, Buzinesh Badada, Ababa Tujuba, Aregash Sakata, Kebene Gidissa, Selamawit Deresa and Gadisse Tamiru
Research & Reviews: Journal of Medical and Health Sciences e-issn: 2319-9865 www.rroij.com Prevalence of Premenstrual Syndrome and Coping Mechanism among Female Students of Guder Preparatory School, West
More information1 de 13 22/03/ :17 p.m.
1 de 13 22/03/2014 05:17 p.m. Premenstrual syndrome Updated 2013 Aug 14 05:00:00 PM: SSRIs may be effective for reducing PMS symptoms (Cochrane Database Syst Rev 2013 Jun 7) view update Show more updates
More informationInformation for you. Managing premenstrual syndrome (PMS) What is PMS?
Managing premenstrual syndrome (PMS) Information for you Published in August 2009 What is PMS? Premenstrual syndrome or PMS is the name given to a collection of physical and emotional symptoms that can
More informationDay-to-day co-variations of psychological and physical symptoms of the menstrual cycle: Insights to individual differences in steroid reactivity
Psychoneuroendocrinology (2010) 35, 350 363 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/psyneuen Day-to-day co-variations of psychological and physical symptoms of the
More informationInternational Journal of Basic and Applied Physiology
Effect Of Anemia On Premenstrual Syndrome In Adolescent Girls Mitesh Sinha*, Archana H Patel*, Shobha Naik**, J.M.Jadeja*** *Resident, **Add. Professor, ***Professor,Department of Physiology,B. J. Medical
More informationHow Neurosteroids Modulate Seizures in Children and Adults November 30, 2012
How Neurosteroids Modulate Seizures in Children and Adults November 30, 2012 Page B. Pennell, MD Brigham and Women s Hospital Harvard Medical School Boston, MA American Epilepsy Society Annual Meeting
More informationRunning head: DEPRESSIVE DISORDERS 1
Running head: DEPRESSIVE DISORDERS 1 Depressive Disorders: DSM-5 Name: Institution: DEPRESSIVE DISORDERS 2 Abstract The 2013 update to DSM-5 saw revisions of the psychiatric nomenclature, diagnostic criteria,
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationClinical Study A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
Obstetrics and Gynecology International Volume 2013, Article ID 487143, 9 pages http://dx.doi.org/10.1155/2013/487143 Clinical Study A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationPremenstrual Dysphoric Disorder
CE/CME Premenstrual Dysphoric Disorder Diagnosis and Management in Primary Care Jovanka Rajic, MSN, RN, NP, FNP-C, PHN, Stefanie A. Varela, RN, PHN, MSN-EDU, FNP, WHNP-BC, PhD The severe psychiatric and
More informationPremenstrual Syndrome
page 1 Premenstrual Syndrome Q: What is premenstrual syndrome (PMS)? A: Premenstrual (pree-men-struhl) syndrome (PMS) is a group of symptoms linked to the menstrual cycle. PMS symptoms occur 1 to 2 weeks
More informationPRESCRIBING INFORMATION CHLORDIAZEPOXIDE. Chlordiazepoxide HCl Capsules USP. 5, 10 and 25 mg. Anxiolytic
PRESCRIBING INFORMATION CHLORDIAZEPOXIDE Chlordiazepoxide HCl Capsules USP 5, 10 and 25 mg Anxiolytic AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road Unit #1 June 27, 2012 Vaughan, Ontario L4K
More informationA Review of Treatment and Management Modalities for Premenstrual Dysphoric Disorder
A Review of Treatment and Management Modalities for Premenstrual Dysphoric Disorder KELLI KELDERHOUSE, MSN, RN, FNP-C JULIE SMITH TAYLOR, PhD, RN, WHNP-BC Approximately 5 percent to 8 percent of women
More informationKeywords Premenstrual syndrome, menstrual phase, pre-ovulatory phase, post-ovulatory phase, PRISM calendar.
Advan Educational Institute & Research Centre 2017 Original Article Measure the Symptoms Related to Pre-Menstrual Syndrome Among Married and Unmarried Females During their Reproductive Life Span. Sonya
More informationEFFECTS OF CALCIUM SUPPLEMENT THERAPY IN WOMEN WITH PREMENSTRUAL SYNDROME
ORIGINAL ARTICLE EFFECTS OF CALCIUM SUPPLEMENT THERAPY IN WOMEN WITH PREMENSTRUAL SYNDROME Zinat Ghanbari, Fedieh Haghollahi, Mamak Shariat 1 *, Abbas Rahimi Foroshani 2, Maryam Ashrafi 3 ValiAsr Reproductive
More informationMethamphetamine Abuse During Pregnancy
Methamphetamine Abuse During Pregnancy Robert Davis, MD / r.w.davismd@gmail.com ❶ Statistics ❷ Pregnancy Concerns ❸ Postpartum Concerns ❹ Basic Science ❺ Best Practice Guidelines ❻ Withdrawal ❼ Recovery
More informationWhen the Bough Breaks
Avoiding Crisis and the Loss of Life by Recognizing and Treating Angela Burling RN MSN Chris Raines MSN RN APRN-BC When the Bough Breaks Angela s Story Raines and Burling 1 A rare but devastatingcondition,
More informationDaily Record of Severity of Problems (DRSP): reliability and validity
Arch Womens Ment Health (2006) 9: 41 49 DOI 10.1007/s00737-005-0103-y Original contribution Daily Record of Severity of Problems (DRSP): reliability and validity J. Endicott 1, J. Nee 1, and W. Harrison
More informationRole of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews
More informationTherapeutic Cohort Results
Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7
More informationPremenstrual Syndrome and Premenstrual Dysphoric Disorder: Symptoms and Cluster Influences
The Open Psychiatry Journal, 2009, 3, 47-57 47 Open Access Premenstrual Syndrome and Premenstrual Dysphoric Disorder: Symptoms and Cluster Influences Faustino R. Pérez-López *,1, Peter Chedraui 2, Gonzalo
More informationEvaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome
Received: 9 Jun. 2010 Accepted: 21 Sep. 2010 Original Article Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome Nahid Fathizadeh*, Elham
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationMar 6, The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly
Mar 6, 2017. The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly effective treatment for the symptoms of PMS and PMDD. The
More informationAntidepressants and Sedatives. David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School
Antidepressants and Sedatives David G. Standaert, M.D., Ph.D. Massachusetts General Hospital Harvard Medical School Depression A frequent problem, affecting up to 5% of the population Common presentations
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationWARNING LETTER. (F)or the prevention of pregnancy in women who elect to use an oral
~t-t\ Si-Vf('i.s '&, 5~ (: ~EPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Reinhard Franzen President & Chief Executive
More informationMonth-Long Hormone Assessment: What goes up must come down. Disclaimer. Aims and Objectives. George Gillson MD PhD
Month-Long Hormone Assessment: What goes up must come down George Gillson MD PhD 1 Disclaimer The information presented in this Webinar is the opinion of Dr. Gillson based on his research and experience.
More informationMANAGEMENT OF PREMENSTRUAL DISORDERS
Review Article MANAGEMENT OF PREMENSTRUAL DISORDERS Anisha Nakulan Assistant Professor, Department of Psychiatry, Amala Institute of Medical Sciences, Thrissur. Correspondence: Department of Psychiatry,
More informationNeuroendocrine Evaluation
Elizabeth Lee Vliet, M.D. Medical Director Neuroendocrine Evaluation When women have health concerns they usually prefer to discuss them with another woman. Dr. Vliet is a national expert on hormone-related
More informationChapter-IV. Blood pressure and heart rate variability as function of ovarian cycle in young women
Blood pressure and heart rate variability as function of ovarian cycle in young women INTRODUCTION In human females, the menstrual cycle begins with the onset of menstrual flow on day 1. The menstrual
More informationJMSCR Volume 03 Issue 04 Page April 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Prevalence of Pre-Menstrual Syndrome in Medical Student Population and Their Relief Measures - A Cross Sectional Study Authors Gantala
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 338 J ANUARY 22, 1998 NUMBER 4 DIFFERENTIAL BEHAVIORAL EFFECTS OF GONADAL STEROIDS IN WOMEN WITH AND IN
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationTherapeutic Cohort Results
Patient: PAGE LOVE DOB: January 11, 1983 Sex: F MRN: 1232704193 Order Number: J9020008 Completed: July 08, 2016 Received: July 02, 2016 Collected: July 01, 2016 Aum Healing Center Sarika Arora MD 332 Newbury
More informationMental Health and Women s Health
Disclosure information I have nothing to disclose. Mental Health and Women s Health Ellen Haller, M.D. Professor of Clinical UCSF Department of Learning Objectives Know what to do when a pt c/o PMS/PMDD
More informationUsing the DSM-5 in the Differential Diagnosis of Depression
Using the DSM-5 in the Differential Diagnosis of Depression Wayne Bentham, MD Clinical Assistant Professor Department of Psychiatry and Behavioral Sciences University of Washington School of Medicine Depressive
More informationDepressive and Bipolar Disorders
Depressive and Bipolar Disorders Symptoms Associated with Depressive and Bipolar Disorders Characteristics of mood symptoms Affects a person s well being, school, work, or social functioning Continues
More informationClass Objectives. Depressive Disorders 10/7/2013. Chapter 7. Depressive Disorders. Next Class:
Chapter 7 Class Objectives Depressive Disorders - Major Depressive Disorder - Persistent Depressive Disorder - Disruptive Mood Dysregulation Disorder - Premenstrual Dysphoric Disorder (PMDD) Next Class:
More informationAssociations between Plasma 25-Hydroxyvitamin D, Hormonal Contraceptives, and Premenstrual Symptoms
Associations between Plasma 25-Hydroxyvitamin D, Hormonal Contraceptives, and Premenstrual Symptoms by Alicia Jarosz A thesis submitted in conformity with the requirements for the degree of Master of Science
More informationApproximately 75% of women experience a premenstrual
Premenstrual dysphoric disorder: How to alleviate her suffering Accurate diagnosis, tailored treatments can greatly improve women s quality of life Laura Wakil, MD Third-Year Psychiatry Resident Samantha
More informationUrine 18/10/ :10 Urine: 18/10/ :05 Urine: 18/10/ : cm Menses Status: Pre-Menopausal - Irregular 26/07/2014
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More information2006 CE Series Lesson Two An Overview of The Premenstrual Syndrome ACPE Universal Program No H01 Expiration Date: 1/31/09
2006 CE Series Lesson Two An Overview of The Premenstrual Syndrome ACPE Universal Program No. 406-000-06-002-H01 Expiration Date: 1/31/09 by H. David Bergman, Ph.D. Dean, Southwestern Oklahoma State University,
More informationFREQUENCY OF PREMENSTRUAL SYNDROME IN WORKING WOMEN VS HOUSEWIVES IN PESHAWAR
ORIGINAL ARTICLE FREQUENCY OF PREMENSTRUAL SYNDROME IN WORKING WOMEN VS HOUSEWIVES IN PESHAWAR Musarrat Jabeen, Fouzia Gul Department of Obstetrics and Gynecology, DHQ Women and Children Hospital, KUST
More informationSubstance and Medication Induced Mood Disorders KELLY GODECKE, MD PSYCHIATRY DEPARTMENT UNIVERSITY OF UTAH
Substance and Medication Induced Mood Disorders KELLY GODECKE, MD PSYCHIATRY DEPARTMENT UNIVERSITY OF UTAH Substance Induced Depressive Disorder A. A prominent and persistent disturbance in mood that predominates
More informationBACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive
BACKGROUNDER Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive Studies find that increased chances of ovulation, menstrual
More information8605 SW Creekside Place Beaverton, OR Phone: Fax: Samples Collected. Samples Received 06/21/2017
TEST RESULTS Ordering Provider: Getuwell Clinic Patient Name: Patient Phone Number: 555 555 5555 Gender Female DOB 6/9/1978 (39 yrs) Menses Status Pre-Menopausal 8605 SW Creekside Place Beaverton, OR 97008
More informationManaging premenstrual syndrome (PMS)
Information for you Published in March 2018 Managing premenstrual syndrome (PMS) About this information This information is for you if you have, or think you have, premenstrual syndrome (PMS) and want
More informationTEST REPORT # U. Patient Name: Sleep Balance Patient Phone Number: TEST NAME RESULTS 07/30/18 RANGE
TEST REPORT Ordering Provider: John Doe, ND 8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636 Samples Received 08/06/18 Report Date 08/10/18 Samples Collected Urine - 07/30/18
More informationDownloaded from umj.umsu.ac.ir at 11: on Friday March 8th 2019
* 1392/06/31 1392/04/26 :. : DSM-IV PMS. / ICD-10 / DSM-IV PMS : PMS. / / / PMS...(p
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More information11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides
Treatment for Anxiety Disorders Benzodiazepines and Other Anxiolytics Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Ethanol Barbiturates and related
More informationOne Day Hormone Check
One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND
More informationASWB LMSW Exam. Volume: 261 Questions
Volume: 261 Questions Question No: 1 Lisa is a social worker who has received a case referred for possible child abuse. She realizes keeping the children safe is her top priority. The household consists
More informationUrinary Hormone Metabolites Estrogen Elite
Test Name Result Range Urinary Estrogens Estradiol 3.71 H 0.78-1.79 µg/g Cr Premeno-luteal or ERT Estrone 10.95 H 2.27-5.22 µg/g Cr Premeno-luteal or ERT Estriol 3.19 H 0.78-1.98 µg/g Cr Premeno-luteal
More informationAim of the present study
Introduction For any woman all over the world, menstruation, pregnancy and menopause are major bodily events in life. Amongst all these, women suffering from menstrual disorders are countless. Premenstrual
More informationPremenstrual Syndrome: Evidence for Symptom Stability Across Cycles
BLOCH, PREMENSTRUAL Am J Psychiatry SCHMIDT, SYNDROME 154:12, AND RUBINOW December 1997 Premenstrual Syndrome: Evidence for Symptom Stability Across Cycles Miki Bloch, M.D., Peter J. Schmidt, M.D., and
More informationPremenstrual Dysphoric Disorder - A Review of Neural and Cognitive Changes in Women with PMDD PREMENSTRUAL DYSPHORIC DISORDER 1
PREMENSTRUAL DYSPHORIC DISORDER 1 Premenstrual Dysphoric Disorder - A Review of Neural and Cognitive Changes in Women with PMDD Bachelor Degree Project in Cognitive Neuroscience Basic level 22.5 ECTS Spring
More informationNeurobiology of Aggression and Violence: Systems, Intervention, and Impact
Neurobiology of Aggression and Violence: Systems, Intervention, and Impact Neal G. Simon, Ph. D. Professor Dept. of Biological Sciences Lehigh University Lecture Outline 1. Overview 2. Regulatory Systems
More informationCannabinoids and Mental Health
Cannabinoids and Mental Health https://upload.wikimedia.org/wikipedia/commons Karen M. Lounsbury, PhD Professor of Pharmacology 802-656-3231, Karen.lounsbury@uvm.edu Objectives Describe the underlying
More information